NO320150B1 - Protein med evne til a inhibere kollagenstimulert blodplateaggregering og forhindre interaksjoner mellom kollagen og von Willebrands faktor (vWF), fremgangsmate for fremstilling derav, farmasoytisk preparat som omfatter det, medisinsk anordning som er belagt med det, samt anvendelser derav for fremstilling av medikamenter. - Google Patents

Protein med evne til a inhibere kollagenstimulert blodplateaggregering og forhindre interaksjoner mellom kollagen og von Willebrands faktor (vWF), fremgangsmate for fremstilling derav, farmasoytisk preparat som omfatter det, medisinsk anordning som er belagt med det, samt anvendelser derav for fremstilling av medikamenter. Download PDF

Info

Publication number: NO320150B1
Authority: NO; Norway
Prior art keywords: collagen; protein; platelet aggregation; vwf; von willebrand
Prior art date: 1993-07-01

Application number

NO19950732A

Other languages

English (en)

Norwegian (no)

Other versions

NO950732L (no

NO950732D0 (no

Inventor

Guido Melzer

Juergen Hemberger

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-07-01

Filing date

1995-02-27

Publication date

2005-10-31

1995-02-27 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

1995-02-27 Publication of NO950732L publication Critical patent/NO950732L/no

1995-02-27 Publication of NO950732D0 publication Critical patent/NO950732D0/no

2005-10-31 Publication of NO320150B1 publication Critical patent/NO320150B1/no

Links

102000004169 proteins and genes Human genes 0.000 title claims abstract description 64
108090000623 proteins and genes Proteins 0.000 title claims abstract description 64
108010035532 Collagen Proteins 0.000 title claims abstract description 40
102000008186 Collagen Human genes 0.000 title claims abstract description 40
229920001436 collagen Polymers 0.000 title claims abstract description 40
208000010110 spontaneous platelet aggregation Diseases 0.000 title claims abstract description 25
229960001134 von willebrand factor Drugs 0.000 title claims abstract description 25
108010047303 von Willebrand Factor Proteins 0.000 title claims abstract description 22
102100036537 von Willebrand factor Human genes 0.000 title claims abstract description 22
238000000034 method Methods 0.000 title claims abstract description 9
230000003993 interaction Effects 0.000 title claims description 10
238000004519 manufacturing process Methods 0.000 title claims description 8
229940079593 drug Drugs 0.000 title claims description 5
239000003814 drug Substances 0.000 title claims description 5
230000002401 inhibitory effect Effects 0.000 title description 5
238000002360 preparation method Methods 0.000 title description 3
239000008194 pharmaceutical composition Substances 0.000 title 1
241000237902 Hirudo medicinalis Species 0.000 claims abstract description 12
208000007536 Thrombosis Diseases 0.000 claims abstract description 8
238000011282 treatment Methods 0.000 claims abstract description 6
239000011248 coating agent Substances 0.000 claims abstract description 5
238000000576 coating method Methods 0.000 claims abstract description 5
210000003296 saliva Anatomy 0.000 claims description 17
238000001962 electrophoresis Methods 0.000 claims description 8
239000000825 pharmaceutical preparation Substances 0.000 claims description 8
238000000338 in vitro Methods 0.000 claims description 5
210000001124 body fluid Anatomy 0.000 claims description 4
239000010839 body fluid Substances 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 3
238000001727 in vivo Methods 0.000 claims description 3
108010058683 Immobilized Proteins Proteins 0.000 claims description 2
239000003146 anticoagulant agent Substances 0.000 claims description 2
229940127219 anticoagulant drug Drugs 0.000 claims description 2
239000006071 cream Substances 0.000 claims description 2
239000003527 fibrinolytic agent Substances 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
229960000103 thrombolytic agent Drugs 0.000 claims description 2
239000002994 raw material Substances 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 11
238000000746 purification Methods 0.000 abstract description 9
230000015572 biosynthetic process Effects 0.000 abstract description 4
239000000463 material Substances 0.000 abstract description 3
239000000287 crude extract Substances 0.000 abstract description 2
238000002955 isolation Methods 0.000 abstract description 2
230000002265 prevention Effects 0.000 abstract description 2
230000004913 activation Effects 0.000 abstract 1
230000000903 blocking effect Effects 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
238000009877 rendering Methods 0.000 abstract 1
230000001732 thrombotic effect Effects 0.000 abstract 1
235000018102 proteins Nutrition 0.000 description 50
210000001772 blood platelet Anatomy 0.000 description 13
239000000872 buffer Substances 0.000 description 10
230000005764 inhibitory process Effects 0.000 description 9
102000007625 Hirudins Human genes 0.000 description 7
108010007267 Hirudins Proteins 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 7
229940006607 hirudin Drugs 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
108010027805 Azocoll Proteins 0.000 description 5
241000545744 Hirudinea Species 0.000 description 5
230000002776 aggregation Effects 0.000 description 5
238000004220 aggregation Methods 0.000 description 5
238000003556 assay Methods 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
231100000673 dose–response relationship Toxicity 0.000 description 5
210000002381 plasma Anatomy 0.000 description 5
238000002474 experimental method Methods 0.000 description 4
238000005227 gel permeation chromatography Methods 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
231100000252 nontoxic Toxicity 0.000 description 4
230000003000 nontoxic effect Effects 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
102000029816 Collagenase Human genes 0.000 description 3
108060005980 Collagenase Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
-1 PAF acetates Chemical class 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000003366 colagenolytic effect Effects 0.000 description 3
229960002424 collagenase Drugs 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
239000000499 gel Substances 0.000 description 3
238000011534 incubation Methods 0.000 description 3
238000005259 measurement Methods 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
210000004623 platelet-rich plasma Anatomy 0.000 description 3
230000002797 proteolythic effect Effects 0.000 description 3
239000000523 sample Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
241000237664 Haementeria officinalis Species 0.000 description 2
241000282412 Homo Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
108090000190 Thrombin Proteins 0.000 description 2
102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
235000011148 calcium chloride Nutrition 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
108010051489 calin Proteins 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000005018 casein Substances 0.000 description 2
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
235000021240 caseins Nutrition 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
229960004072 thrombin Drugs 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
YMMPZCZOLKBHAP-IHPCNDPISA-N (2s)-2-[[(2s)-1-[2-[[2-[[(2s)-1-[2-(phenylmethoxycarbonylamino)acetyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)CNC(=O)[C@H]1N(C(=O)CNC(=O)OCC=2C=CC=CC=2)CCC1 YMMPZCZOLKBHAP-IHPCNDPISA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
240000002470 Amphicarpaea bracteata Species 0.000 description 1
208000002109 Argyria Diseases 0.000 description 1
206010003178 Arterial thrombosis Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
102000012422 Collagen Type I Human genes 0.000 description 1
108010022452 Collagen Type I Proteins 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108010067770 Endopeptidase K Proteins 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
241000193159 Hathewaya histolytica Species 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
241000237678 Hirudinidae Species 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
108010001014 Plasminogen Activators Proteins 0.000 description 1
102000001938 Plasminogen Activators Human genes 0.000 description 1
229940123251 Platelet activating factor antagonist Drugs 0.000 description 1
206010036030 Polyarthritis Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
208000001435 Thromboembolism Diseases 0.000 description 1
208000024248 Vascular System injury Diseases 0.000 description 1
208000012339 Vascular injury Diseases 0.000 description 1
206010047249 Venous thrombosis Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
239000011149 active material Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000004931 aggregating effect Effects 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
230000002785 anti-thrombosis Effects 0.000 description 1
229960004676 antithrombotic agent Drugs 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
108010083526 asialo-von Willebrand Factor Proteins 0.000 description 1
OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
230000008901 benefit Effects 0.000 description 1
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
238000005842 biochemical reaction Methods 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
150000001734 carboxylic acid salts Chemical class 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000011210 chromatographic step Methods 0.000 description 1
238000011097 chromatography purification Methods 0.000 description 1
235000013985 cinnamic acid Nutrition 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
238000001085 differential centrifugation Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical compound NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
108010005808 hementin Proteins 0.000 description 1
230000023597 hemostasis Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
230000003100 immobilizing effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
238000009236 leech therapy Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
230000035772 mutation Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229940127126 plasminogen activator Drugs 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
230000010118 platelet activation Effects 0.000 description 1
208000030428 polyarticular arthritis Diseases 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000031915 positive regulation of coagulation Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
229910000343 potassium bisulfate Inorganic materials 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
239000012488 sample solution Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000012209 synthetic fiber Substances 0.000 description 1
229920002994 synthetic fiber Polymers 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
210000002435 tendon Anatomy 0.000 description 1
238000012360 testing method Methods 0.000 description 1
239000003848 thrombocyte activating factor antagonist Substances 0.000 description 1
150000003628 tricarboxylic acids Chemical class 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
229940086542 triethylamine Drugs 0.000 description 1
230000002792 vascular Effects 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/855—Proteins from animals other than mammals or birds
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/855—Proteins from animals other than mammals or birds
- Y10S530/858—Proteins from animals other than mammals or birds insects; venom

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Tropical Medicine & Parasitology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Toxicology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Diabetes (AREA)
Immunology (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO19950732A 1993-07-01 1995-02-27 Protein med evne til a inhibere kollagenstimulert blodplateaggregering og forhindre interaksjoner mellom kollagen og von Willebrands faktor (vWF), fremgangsmate for fremstilling derav, farmasoytisk preparat som omfatter det, medisinsk anordning som er belagt med det, samt anvendelser derav for fremstilling av medikamenter. NO320150B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP93110528		1993-07-01
PCT/EP1994/002087 WO1995001375A1 (en)	1993-07-01	1994-06-28	Inhibitor of collagen-stimulated platelet aggregation

Publications (3)

Publication Number	Publication Date
NO950732L NO950732L (no)	1995-02-27
NO950732D0 NO950732D0 (no)	1995-02-27
NO320150B1 true NO320150B1 (no)	2005-10-31

Family

ID=8213032

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19950732A NO320150B1 (no)	1993-07-01	1995-02-27	Protein med evne til a inhibere kollagenstimulert blodplateaggregering og forhindre interaksjoner mellom kollagen og von Willebrands faktor (vWF), fremgangsmate for fremstilling derav, farmasoytisk preparat som omfatter det, medisinsk anordning som er belagt med det, samt anvendelser derav for fremstilling av medikamenter.

Country Status (22)

Country	Link
US (1)	US5710131A (de)
EP (1)	EP0662088B1 (de)
JP (1)	JP3742429B2 (de)
KR (2)	KR100445309B1 (de)
CN (1)	CN1134451C (de)
AT (1)	ATE210679T1 (de)
AU (1)	AU680929B2 (de)
CA (1)	CA2143416C (de)
CZ (1)	CZ287472B6 (de)
DE (1)	DE69429419T2 (de)
DK (1)	DK0662088T3 (de)
ES (1)	ES2169080T3 (de)
HU (1)	HU214580B (de)
NO (1)	NO320150B1 (de)
PL (1)	PL180752B1 (de)
PT (1)	PT662088E (de)
RU (1)	RU2160280C2 (de)
SK (1)	SK282961B6 (de)
TW (1)	TW281678B (de)
UA (1)	UA41332C2 (de)
WO (1)	WO1995001375A1 (de)
ZA (1)	ZA944738B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2153760B1 (es) *	1998-11-25	2001-07-01	Univ Barcelona Autonoma	Inhibidor de metalocarboxipeptidasas como agente fibrinolitico.
JP4805461B2 (ja) *	1999-03-18	2011-11-02	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	血小板接着の阻止用タンパク質
DE60038675T2 (de)	1999-05-07	2009-07-02	Sanofi-Aventis Deutschland Gmbh	Rekombinantes plättchenkollagenrezeptorglykoprotein und dessen pharmazeutische verwendung
MY128992A (en) *	2000-08-25	2007-03-30	Merck Patent Gmbh	Saratin for inhibiting platelet adhesion to collagen
GB0031448D0 (en)	2000-12-22	2001-02-07	Leuven K U Res & Dev	Inhibition of the vWF-collagen interaction by anti-human vWF monoclonal antibody (82D6A3) results in abolition of in vivo arterial platelet thrombus formation
RU2203074C2 (ru) *	2001-02-12	2003-04-27	Амиров Наиль Хабибулович	Способ лечения ревматоидного артрита и остеоартроза
JP2008512097A (ja) *	2004-09-07	2008-04-24	アーケミックスコーポレイション	アプタマー医薬品化学
US7566701B2 (en) *	2004-09-07	2009-07-28	Archemix Corp.	Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
KR20070101227A (ko)	2004-09-07	2007-10-16	아케믹스 코포레이션	폰 빌레브란트 인자에 대한 앱타머 및 이의 혈전증치료제로서의 용도
US20060286548A1 (en) *	2005-06-16	2006-12-21	Gregory Liposky	Method of making recombinant human antibodies for use in biosensor technology
US7691839B2 (en)	2005-09-28	2010-04-06	Biovascular, Inc.	Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation
US20110034396A1 (en) *	2005-09-28	2011-02-10	Biovascular, Inc.	Methods and compositions for inhibiting cell migration and treatment of inflammatory conditions
TWI391143B (zh) *	2005-11-04	2013-04-01	Otsuka Pharma Co Ltd	血小板凝集抑制劑組成物
US20080015145A1 (en) *	2006-07-11	2008-01-17	Maria Gyongyossy-Issa	Mimotope receptors and inhibitors for platelet-platelet and platelet-endothelium interactions
US20090203766A1 (en) *	2007-06-01	2009-08-13	Archemix Corp.	vWF aptamer formulations and methods for use
EP2316465A1 (de) *	2009-10-15	2011-05-04	Centre National De La Recherche Scientifique	Verwendung von Extrakt von Blutegelspeichel als antibakterielles Mittel zur Herstellung unterschiedlicher Zusammensetzungen
WO2012104866A1 (en)	2011-01-31	2012-08-09	Council Of Scientific & Industrial Research	Chiral 1-(4-methylphenylmethyl)-5-oxo-{n-[(3-t-butoxycarbonyl- aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamides as inhibitors of collagen induced platelet activation and adhesion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2070116T3 (es) *	1986-05-30	1995-06-01	Scripps Research Inst	Peptidos que inhiben la union del factor von willebrand.
US5238919A (en) *	1986-05-30	1993-08-24	Scipps Clinic And Research Foundation	Peptides that inhibit von Willebrand Factor binding to the platelet SPIB receptor
US5256559A (en) *	1988-03-04	1993-10-26	Biogen, Inc.	Methods and compositions for inhibiting platelet aggregation
IL86856A0 (en) *	1988-06-24	1988-11-30	Yissum Res Dev Co	Bovine xa factor and pharmaceutical compositions containing the same
WO1990006128A1 (en) *	1988-12-05	1990-06-14	Biogen, Inc.	Methods and compositions for inhibiting platelet aggregation
CA2008116C (en) *	1989-02-23	2001-11-20	Thomas Weller	Glycine derivatives
CA2052486A1 (en) *	1990-10-09	1992-04-10	Thomas M. Connolly	Protein for inhibiting collagen-stimulated platelet aggregation
GB9022040D0 (en) *	1990-10-10	1990-11-21	Biopharm Ltd	Platelet adhesion inhibitor
US5342830A (en) *	1990-11-16	1994-08-30	Cor Therapeutics, Inc.	Antithrombosis agents

1994
- 1994-06-28 PL PL94307726A patent/PL180752B1/pl not_active IP Right Cessation
- 1994-06-28 EP EP94923690A patent/EP0662088B1/de not_active Expired - Lifetime
- 1994-06-28 CN CNB941904229A patent/CN1134451C/zh not_active Expired - Fee Related
- 1994-06-28 ES ES94923690T patent/ES2169080T3/es not_active Expired - Lifetime
- 1994-06-28 PT PT94923690T patent/PT662088E/pt unknown
- 1994-06-28 UA UA95028198A patent/UA41332C2/uk unknown
- 1994-06-28 CZ CZ1995528A patent/CZ287472B6/cs not_active IP Right Cessation
- 1994-06-28 DE DE69429419T patent/DE69429419T2/de not_active Expired - Fee Related
- 1994-06-28 SK SK270-95A patent/SK282961B6/sk unknown
- 1994-06-28 US US08/392,970 patent/US5710131A/en not_active Expired - Fee Related
- 1994-06-28 AT AT94923690T patent/ATE210679T1/de not_active IP Right Cessation
- 1994-06-28 KR KR1019950700766A patent/KR100445309B1/ko not_active Expired - Fee Related
- 1994-06-28 JP JP50326095A patent/JP3742429B2/ja not_active Expired - Fee Related
- 1994-06-28 CA CA002143416A patent/CA2143416C/en not_active Expired - Fee Related
- 1994-06-28 AU AU73836/94A patent/AU680929B2/en not_active Ceased
- 1994-06-28 HU HU9500613A patent/HU214580B/hu not_active IP Right Cessation
- 1994-06-28 RU RU95108596/13A patent/RU2160280C2/ru not_active IP Right Cessation
- 1994-06-28 WO PCT/EP1994/002087 patent/WO1995001375A1/en not_active Ceased
- 1994-06-28 KR KR10-2004-7002282A patent/KR100455639B1/ko not_active Expired - Fee Related
- 1994-06-28 DK DK94923690T patent/DK0662088T3/da active
- 1994-06-30 ZA ZA944738A patent/ZA944738B/xx unknown
- 1994-07-18 TW TW083106615A patent/TW281678B/zh active
1995
- 1995-02-27 NO NO19950732A patent/NO320150B1/no unknown

Also Published As

Publication number	Publication date
KR950703004A (ko)	1995-08-23
ZA944738B (en)	1995-02-15
KR100445309B1 (ko)	2004-11-12
KR100455639B1 (ko)	2004-11-09
ATE210679T1 (de)	2001-12-15
CN1111058A (zh)	1995-11-01
CZ52895A3 (en)	1995-09-13
PL180752B1 (pl)	2001-04-30
CA2143416A1 (en)	1995-01-12
PT662088E (pt)	2002-06-28
AU680929B2 (en)	1997-08-14
US5710131A (en)	1998-01-20
HU214580B (hu)	1998-04-28
PL307726A1 (en)	1995-06-12
HU9500613D0 (en)	1995-04-28
UA41332C2 (uk)	2001-09-17
CZ287472B6 (en)	2000-12-13
ES2169080T3 (es)	2002-07-01
SK27095A3 (en)	1995-08-09
CA2143416C (en)	2003-06-10
CN1134451C (zh)	2004-01-14
WO1995001375A1 (en)	1995-01-12
HUT71399A (en)	1995-11-28
AU7383694A (en)	1995-01-24
EP0662088A1 (de)	1995-07-12
SK282961B6 (sk)	2003-01-09
DK0662088T3 (da)	2002-02-25
KR20040030124A (ko)	2004-04-08
DE69429419T2 (de)	2002-08-01
DE69429419D1 (de)	2002-01-24
TW281678B (de)	1996-07-21
JP3742429B2 (ja)	2006-02-01
EP0662088B1 (de)	2001-12-12
JPH08500848A (ja)	1996-01-30
RU2160280C2 (ru)	2000-12-10
NO950732L (no)	1995-02-27
NO950732D0 (no)	1995-02-27

Publication	Publication Date	Title
NO320150B1 (no)	2005-10-31	Protein med evne til a inhibere kollagenstimulert blodplateaggregering og forhindre interaksjoner mellom kollagen og von Willebrands faktor (vWF), fremgangsmate for fremstilling derav, farmasoytisk preparat som omfatter det, medisinsk anordning som er belagt med det, samt anvendelser derav for fremstilling av medikamenter.
Karczewski et al.	1994	Disagregin is a fibrinogen receptor antagonist lacking the Arg-Gly-Asp sequence from the tick, Ornithodoros moubata.
CA1335666C (en)	1995-05-23	Extraction and purification of an anticoagulant principle from the south american leech, haementeria ghilianii
HUP0200353A2 (hu)	2002-05-29	Fehérje, vérlemezkék tapadásának gátlására
EP0907724B1 (de)	2007-03-21	Von willebrand-faktor multimerase
US6025330A (en)	2000-02-15	Inhibitors of fibrin cross-linking and/or transglutaminases
KR100335536B1 (ko)	2002-11-11	트롬빈억제제
Rebello et al.	1997	Antithrombotic efficacy of a recombinant nematode anticoagulant peptide (rNAP5) in canine models of thrombosis after single subcutaneous administration
AU659807B2 (en)	1995-06-01	Platelet adhesion inhibitor
JPH11507664A (ja)	1999-07-06	第ｖｉｉｉ因子由来の第ｉｘ因子結合ペプチド及び血液凝固のインヒビターとしてのそれらの使用
Thiagarajan et al.	1999	Mechanisms of antithrombotic drugs
Bykowska et al.	1985	Anticoagulant properties of extracellular slime substance produced by Staphylococcus epidermidis
JP3878668B2 (ja)	2007-02-07	血栓性疾患の治療
Spaet et al.	1960	Induction in rabbits of activity against human blood thromboplastin
Muramatsu et al.	1997	Antithrombotic effects of NF-6505, a novel anion-binding exosite inhibitor
Cook et al.	1995	Molecular and cellular cardiology: an antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey
MXPA99008525A (en)	2000-11-01	Bi- or multifunctional molecules based on a dendroaspin scaffold
IE66266B1 (en)	1995-12-27	Method and therapeutic compositions for the treatment of bleeding disorders